Baird lowered the firm’s price target on Charles River to $270 from $282 and keeps an Outperform rating on the shares. The firm said its Q1 positives outweighed negatives, driving healthy beat. 2Q talked down similarly, primarily timing, tougher comps, and lower volume and less pricing benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- CRL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Charles River announces rare disease gene therapy collaboration with Axovia
- Charles River to perform plasmid production for Ship of Theseus
- Charles River extends gene therapy manufacturing alliance with NUS Medicine
- Charles River price target raised to $290 from $200 at Argus